Prognostic implication of retrocrural lymph node involvement revealed by 18F-FDG PET/CT in patients with uterine cervical cancer

被引:13
|
作者
Im, Hyung-Jun [1 ,3 ,4 ]
Yoon, Hai-Jeon [1 ]
Lee, Eun Seong [1 ,4 ]
Kim, Tae-Sung [1 ]
Kim, Joo-Young [2 ]
Chung, June-Key [3 ]
Kim, Seok-ki [1 ]
Park, Sang-Yoon [2 ]
机构
[1] Natl Canc Ctr, Dept Nucl Med, Goyang Si 410769, Gyeonggi Do, South Korea
[2] Natl Canc Ctr, Ctr Uterine Canc, Goyang Si 410769, Gyeonggi Do, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Nucl Med, Seoul, South Korea
[4] Seoul Natl Univ, WCU Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Yeongeon Dong, South Korea
基金
新加坡国家研究基金会;
关键词
F-18-FDG PET/CT; prognosis; retrocrural lymph node; uterine cervical cancer; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; CARCINOMA; CT;
D O I
10.1097/MNM.0000000000000037
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivesLymph node involvement in cervical cancer is an indication of poor prognosis and the risk tends to increase according to the level of lymph node involvement. However, the specific prognostic significance of retrocrural lymph node involvement has not been well characterized because of its small size and deep location. The aim of this study was to assess its prognostic value.Patients and methodsA total of 217 patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IVA cervical cancer were retrospectively enrolled. All the patients had undergone pretreatment F-18-fluorodeoxy-d-glucose (F-18-FDG) PET/CT. Of these patients 145 were treated with concurrent chemoradiotherapy, and in this group we assessed the relationship of retrocrural lymph node involvement with the risk of disease progression.ResultsRetrocrural lymph node involvement was seen in 7.4% of patients (16/217). All of them had para-aortic lymph node involvement and 56% of the 16 patients (9/16) had concomitant supraclavicular lymph node involvement. In the patients treated with concurrent chemoradiotherapy it was found that the higher the level of F-18-FDG-positive lymph nodes detected in them, the worse the progression-free survival experienced by them (none vs. pelvic, pelvic vs. para-aortic, para-aortic vs. retrocrural; P<0.05); however, there was no difference in progression outcome between retrocrural and supraclavicular areas (P=NS). On multivariate Cox proportional hazard analysis, the highest level of F-18-FDG PET/CT-positive lymph nodes in the para-aortic [hazard ratio (HR) 6.05, 95% confidence interval (CI) 2.18-16.81], retrocrural (HR 17.05, 95% CI 5.34-54.44), and supraclavicular areas (HR 19.56, 95% CI 7.15-53.54) was a significant prognostic factor.ConclusionThe highest level of lymph node involvement in para-aortic, retrocrural, supraclavicular areas was a significant prognostic factor for progression in uterine cervical cancer patients who were treated with concurrent chemoradiotherapy. Retrocrural lymph node involvement shows a similar outcome with supraclavicular involvement, but leads to a worse outcome in terms of progression compared with para-aortic lymph node involvement. (C) 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 50 条
  • [1] Prognostic value of retrocrural lymph node involvement revealed by FDG PET/CT in cervical cancer
    Im, Hyung-Jun
    Kim, Seok-Ki
    Kim, Tae-Sung
    Park, Sang-Yoon
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [2] The role of 18F-FDG PET/CT in pelvic and paraaortic lymph node staging of uterine cervical cancer
    Soydal, C.
    Ibis, E.
    Ortac, F.
    Ozkan, E.
    Kucuk, N. O.
    Kir, K. M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S579 - S579
  • [3] Predictive value of volumetric parameters measured by 18F-FDG PET/CT for lymph node involvement in patients with cervical cancer
    Dutertre, Axelle
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [4] 18F-FDG PET/CT Radiomics Of Cervical Cancer In Predicting Lymph Node Metastasis
    Monaco, L.
    Mathoux, G.
    Crivellaro, C.
    Elisei, F.
    Buda, A.
    Fruscio, R.
    Landoni, C.
    Guerra, L.
    Messa, C.
    De Bernardi, E.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S233 - S234
  • [5] The usefulness of 18F-FDG PET/CT in the evaluation of cervical lymph node metastasis in patients with oral cancer
    Choi, G. H.
    Park, H. J.
    Yu, M. G.
    Kook, M. S.
    Oh, H. K.
    Ryu, S. Y.
    [J]. ORAL ONCOLOGY, 2009, : 167 - 167
  • [6] The maxSUV in tumor and lymph node by 18F-FDG PET/CT as prognostic value in patients with node positive breast cancer
    Kang, S. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 57 : S139 - S139
  • [7] PREDICTION OF LYMPH NODE METASTASIS FROM 18F-FDG PET/CT RADIOMICS OF CERVICAL CANCER
    Monaco, Lavinia
    Mathoux, Gregory
    Crivellaro, Cinzia
    Elisei, Federica
    Buda, Alessandro
    Fruscio, Robert
    Landoni, Claudio
    Guerra, Luca
    Messa, Cristina
    De Bernardi, Elisabetta
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [8] Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy
    Bas B. Koolen
    Renato A. Valdés Olmos
    Paula H. M. Elkhuizen
    Wouter V. Vogel
    Marie-Jeanne T. F. D. Vrancken Peeters
    Sjoerd Rodenhuis
    Emiel J. Th. Rutgers
    [J]. Breast Cancer Research and Treatment, 2012, 135 : 231 - 240
  • [9] Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy
    Koolen, Bas B.
    Olmos, Renato A. Valdes
    Elkhuizen, Paula H. M.
    Vogel, Wouter V.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Rodenhuis, Sjoerd
    Rutgers, Emiel J. Th.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (01) : 231 - 240
  • [10] PROGNOSTIC VALUE OF 18F-FDG PET/CT FOR DETERMINATION OF LYMPH NODE INVOLVEMENT AND STAGE OF THE DISEASE IN PATIENTS WITH ENDOMETRIAL CARCINOMA
    Ozgu, E.
    Oz, M.
    Yildiz, Y.
    Ozgu, B. Salman
    Erkaya, S.
    Gungor, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1128 - 1128